Inhibiting a previously undruggable protein holds promise for treatment of numerous types of cancer.
Blocking a specific protein linked with cancer growth may lead to the development of a breakthrough new class of oncology drugs, a recent study found.
The study, published in the current issue of ACS Chemical Biology, evaluated 6 chemical compounds that inhibit the so-called “oncoprotein” HuR, which binds to RNA and promotes tumor growth.
"These are the first reported small-molecule HuR inhibitors that competitively disrupt HuR-RNA binding and release the RNA, thus blocking HuR function as a tumor-promoting protein," corresponding author Liang Xu said in a press release.
Read more at Specialty Pharmacy TImes: http://bit.ly/1aUR8oP
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More